A Study to Assess the Pharmacokinetic Profile of Prazosin and Cyproheptadine
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The study is an open-label, randomized,2-period, single dose, crossover study in 8 healthy
male/female volunteers. Subjects will be randomized to the following sequences:
(A) Period 1: KT110 - wash-out period - Period 2: Alpress and Periactin marketed tablets ; Or
(B) Period 1: Alpress and Periactin marketed tablets - wash-out period - Period 2: KT110